Braulio Martín Calero

Hospital Universitario de Canarias

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Marta Llanos Muñoz

Hospital Universitario de Canarias

S García Gil

Hospital Universitario de Canarias

José Antonio Pérez Pérez

Universidad de La Laguna

María Micaela Viña Romero

Universidad de La Laguna

Fernando Gutiérrez Nicolás

Hospital Universitario de Canarias

Gloria Julia Nazco Casariego

Hospital Universitario de Canarias

Ruth Tramontani Ramos

Hospital Universitario de Canarias

Isaac Ceballos Lenza

Hospital Universitario de Canarias

Beatriz Carro Alonso

Hospital Clínico Universitario Lozano Blesa

Josefina Cruz

Hospital Universitario de Canarias

Cooperative Institutions

Hospital Universitario de Canarias

Universidad de La Laguna

GEICAM – Spanish Breast Cancer Group

Universidad Europea de Canarias

Cornell University

Hospital Universitario Nuestra Señora de Candelaria

Universidad de Las Palmas de Gran Canaria

Hospital Clínico Universitario Lozano Blesa

Solti

Invictus Medical (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Analysis of KRAS and NRAS mutations in 126 patients with KRAS exon 2 wild type for metastatic colorectal cancer (mCRC) in a single institution.

Journal of Clinical Oncology (2015)

Braulio Martín Calero Marta Llanos B. Alonso Álvarez Raquel Hernández San Gil Eduardo Salido

e14589 Background: To know the prevalence of mutations in the RAS family in our hospital, and to determine the effect of new mutations in KRAS and NRAS in overall survival and progression-free survival. Methods: This is a retrospective observational trial. We selected a group of 126 patients with metastatic colon cancer KRAS exon 2 wild type, who received first-line treatment in our center between 01/2007 and 12/2013. Determination was performed KRAS (exon 3 and 4) and NRAS mutation (exon 2, 3 and 4) by pyrosequencing. Results: We have made the determination of 90 patients (see table below). Of the patients studied, 79% of patients remained RAS wild type. 16% had new mutations: 54% NRAS codon 61, 38% NRAS codon 12 and 8% NRAS codon 13. Regarding the clinical impact, the new RAS wild type group (n = 73) has an overall survival of 30 months (95% CI 20 to 39.7) and a progression-free survival of 8 months (95% CI 7, 5 to 10.1). Mutated RAS group (n = 13) has an overall survival of 29 months (95% CI: 5-52) and a progression-free survival of 8 months (95% CI: 5.6 to 12.3). Conclusions: The frequency of mutations in KRAS/NRAS in our center was similar to clinical trials. In our institution, overall survival and progression-free survival in RAS wild type were similar to the previously reported. RAS mutated patients were not enough to extrapolate conclusions. Mutation Total patients (n = 90) Wild type samples 73 NRAS codon 12 mutant 5 NRAS codon 13 mutant 1 NRAS codon 61 mutant 7 Failed 4

Progression-free survival

10.1200/jco.2015.33.15_suppl.e14589

Cite

Citations (0)

Efecto de los polimorfismos en UGT, SLCO, ABCB y ABCC en la toxicidad del tratamiento con irinotecán

Medicina Clínica (2018)

S García Gil Ruth Tramontani Ramos Gloria Julia Nazco Casariego Marta Llanos Muñoz María Micaela Viña Romero

10.1016/j.medcli.2018.01.016

Cite

Citations (4)

Relationship between primary tumor location and oncogenes mutations in metastatic colorectal cancer

Annals of Oncology (2017)